Delving into the Latest Updates on NACS, Inc. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Neoplasms	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

DNA x RNR	1

[Translation] A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of TAR-200 compared with investigator’s choice of intravesical chemotherapy in subjects with high-risk non-muscle invasive bladder cancer (HR-NMIBC) who have relapsed after Bacillus Calmette-Guérin (BCG) therapy and are not candidates for or choose not to undergo radical cystectomy

主要目的是在BCG治疗末次给药后1年内出现单纯乳头状HR-NMIBC复发且拒绝或不适合接受根治性膀胱切除术(RC)的受试者中，比较接受TAR-200治疗与研究者选择的单药膀胱内化疗的无疾病生存期。

[Translation]

The primary objective was to compare disease-free survival between patients treated with TAR-200 and investigator's choice of single-agent intravesical chemotherapy in subjects with recurrence of isolated papillary HR-NMIBC within 1 year after the last dose of BCG therapy who refused or were not candidates for radical cystectomy (RC).

Start Date27 May 2024

Sponsor / Collaborator

Fisher Clinical Services GmbH

[+7]

CTR20222887

/ Active, not recruitingPhase 3

一项在未接受过BCG治疗的高危非肌层浸润性膀胱癌（HR-NMIBC）受试者中评价TAR-200联合Cetrelimab治疗或TAR-200单药治疗对比膀胱内卡介苗（BCG）治疗的疗效和安全性的III期、开放性、多中心、随机研究

[Translation] A Phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of TAR-200 plus cetrelimab or TAR-200 alone versus intravesical Bacillus Calmette-Guérin (BCG) therapy in subjects with high-risk non-muscle invasive bladder cancer (HR-NMIBC) who have not received BCG treatment

在未接受过BCG治疗的HR-NMIBC（高级别乳头状Ta、任何T1或原位癌[CIS]）受试者中，对比接受TAR-200+IV Cetrelimab治疗（组A）和TAR-200单药治疗（组C）与膀胱内BCG治疗（组B）的无事件生存期（EFS）。

[Translation]

In subjects with BCG-naive HR-NMIBC (high-grade papillary Ta, any T1, or carcinoma in situ [CIS]), event-free survival (EFS) was compared between TAR-200 plus IV Cetrelimab (Arm A) and TAR-200 alone (Arm C) versus intravesical BCG (Arm B).

Start Date10 May 2023

Sponsor / Collaborator

Fisher Clinical Services GmbH

[+5]

100 Clinical Results associated with NACS, Inc.

Login to view more data

0 Patents (Medical) associated with NACS, Inc.

Login to view more data

100 Deals associated with NACS, Inc.

Login to view more data

100 Translational Medicine associated with NACS, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Login to view more data